Compass Therapeutics Welcomes Barry Shin as Chief Financial Officer
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company, has recently announced the appointment of Barry Shin as Chief Financial Officer. With an extensive background in finance and operations, Mr. Shin brings over two decades of experience in the biopharmaceutical industry. He officially joined the Compass team on December 9, 2024.
Thomas Schuetz, MD, PhD, the CEO of Compass Therapeutics, expressed enthusiasm about Barry's appointment during what he describes as a pivotal phase for the company. Schuetz emphasized the key catalysts on the horizon for 2025, including the significant data readout for CTX-009 in the first quarter. He noted, "Barry’s deep expertise in financial and strategic planning, capital markets, and M&A will be invaluable as we advance our clinical and pre-clinical assets." This strategic leadership is seen as crucial to enhance shareholder value during a transformative period.
Insight into Barry Shin's Experience
Mr. Shin’s comprehensive background includes roles as Executive Vice President, Chief Operating Officer, and Chief Financial Officer at Trevena, Inc., where he contributed to developing innovative therapies for central nervous system ailments. His vast experience extends to serving as a Managing Director in Healthcare Investment Banking at prominent firms like Mizuho Securities and Guggenheim Securities. Moreover, Shin started his career advising healthcare and technology sectors in M&A and financing transactions.
Barry Shin's Vision for Compass Therapeutics
Upon his appointment, Mr. Shin stated, "I am thrilled to join Compass during this critical phase. The data from CTX-009 and our pipeline is incredibly promising, and I am eager to contribute to the team’s mission of providing vital therapeutic options to patients in need." He is passionate about utilizing his financial expertise to steer the company's strategic initiatives as it continues its evolution and growth.
About Compass Therapeutics and Its Mission
Founded in 2014, Compass Therapeutics focuses on developing proprietary antibody-based therapeutics aimed at treating various human diseases, particularly in oncology. The company’s innovative approach examines the intricate relationship between angiogenesis, immune response, and tumor growth. Its pipeline comprises novel candidates designed to modulate critical biological pathways essential for an effective anti-tumor response.
Compass Therapeutics aims to advance its therapeutic candidates through clinical trials, utilizing both standalone therapies and combination treatments based on promising clinical and nonclinical data. Their commitment to innovation reflects its dedication to delivering impactful solutions to patients facing challenging health conditions.
Frequently Asked Questions
Who is Barry Shin?
Barry Shin is the newly appointed Chief Financial Officer of Compass Therapeutics, bringing over 20 years of experience in the biopharmaceutical industry.
What are Compass Therapeutics' main areas of focus?
Compass Therapeutics focuses on developing antibody-based therapeutics targeting various oncology conditions, exploring the interplay between angiogenesis and the immune system.
What is CTX-009?
CTX-009 is a key product candidate in Compass Therapeutics’ pipeline, with anticipated data readouts expected to be critical for the company’s future developments.
When did Barry Shin officially join Compass Therapeutics?
Barry Shin officially joined Compass Therapeutics as CFO on December 9, 2024.
What is the mission of Compass Therapeutics?
The mission of Compass Therapeutics is to advance innovative therapeutics for the treatment of serious diseases, particularly through their oncology-focused research and development efforts.
